NYSE:GSK

GlaxoSmithKline Competitors

$36.12
+0.08 (+0.22 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$35.99
Now: $36.12
$36.32
50-Day Range
$33.61
MA: $35.60
$36.69
52-Week Range
$33.26
Now: $36.12
$43.18
Volume359,447 shs
Average Volume5.91 million shs
Market Capitalization$97.26 billion
P/E Ratio11.11
Dividend Yield6.88%
Beta0.67

Competitors

GlaxoSmithKline (NYSE:GSK) Vs. ABT, PFE, NVS, MRK, ABBV, and LLY

Should you be buying GSK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to GlaxoSmithKline, including Abbott Laboratories (ABT), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), and Eli Lilly and (LLY).

GlaxoSmithKline (NYSE:GSK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Valuation and Earnings

This table compares GlaxoSmithKline and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.41
Abbott Laboratories$31.90 billion6.76$3.69 billion$3.2437.59

GlaxoSmithKline has higher revenue and earnings than Abbott Laboratories. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.8% of GlaxoSmithKline shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for GlaxoSmithKline and Abbott Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline34602.23
Abbott Laboratories111502.82

Abbott Laboratories has a consensus price target of $122.0556, suggesting a potential upside of 0.19%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than GlaxoSmithKline.

Dividends

GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. GlaxoSmithKline has increased its dividend for 1 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years.

Volatility and Risk

GlaxoSmithKline has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares GlaxoSmithKline and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKline18.50%29.60%7.11%
Abbott Laboratories10.50%18.19%8.29%

Summary

Abbott Laboratories beats GlaxoSmithKline on 11 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Volatility and Risk

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 10.0% of GlaxoSmithKline shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Pfizer and GlaxoSmithKline's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.00$16.27 billion$2.9512.58
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.41

Pfizer has higher revenue and earnings than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pfizer and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
GlaxoSmithKline18.50%29.60%7.11%

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.2%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Pfizer pays out 52.9% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 1 consecutive years and GlaxoSmithKline has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pfizer and GlaxoSmithKline, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010302.23
GlaxoSmithKline34602.23

Pfizer presently has a consensus price target of $38.5714, suggesting a potential upside of 4.05%. Given Pfizer's higher probable upside, analysts plainly believe Pfizer is more favorable than GlaxoSmithKline.

Summary

Pfizer beats GlaxoSmithKline on 9 of the 15 factors compared between the two stocks.

Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Risk and Volatility

Novartis has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares Novartis and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis14.71%24.39%10.59%
GlaxoSmithKline18.50%29.60%7.11%

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Novartis pays out 39.7% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis has raised its dividend for 1 consecutive years and GlaxoSmithKline has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

9.9% of Novartis shares are owned by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 10.0% of GlaxoSmithKline shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Novartis and GlaxoSmithKline, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24602.33
GlaxoSmithKline34602.23

Novartis currently has a consensus price target of $108.50, suggesting a potential upside of 24.96%. Given Novartis' stronger consensus rating and higher probable upside, research analysts plainly believe Novartis is more favorable than GlaxoSmithKline.

Earnings & Valuation

This table compares Novartis and GlaxoSmithKline's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.50 billion4.18$11.73 billion$5.2416.57
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.41

Novartis has higher revenue and earnings than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Summary

Novartis beats GlaxoSmithKline on 9 of the 15 factors compared between the two stocks.

GlaxoSmithKline (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Insider and Institutional Ownership

11.8% of GlaxoSmithKline shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

GlaxoSmithKline has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares GlaxoSmithKline and Merck & Co., Inc.'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.41
Merck & Co., Inc.$46.84 billion4.12$9.84 billion$5.1914.71

Merck & Co., Inc. has higher revenue and earnings than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Dividends

GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. GlaxoSmithKline has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a summary of current recommendations for GlaxoSmithKline and Merck & Co., Inc., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline34602.23
Merck & Co., Inc.021102.85

Merck & Co., Inc. has a consensus target price of $96.2727, indicating a potential upside of 26.06%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than GlaxoSmithKline.

Profitability

This table compares GlaxoSmithKline and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKline18.50%29.60%7.11%
Merck & Co., Inc.24.33%53.83%16.83%

Summary

Merck & Co., Inc. beats GlaxoSmithKline on 13 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Analyst Recommendations

This is a breakdown of current ratings for AbbVie and GlaxoSmithKline, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121302.75
GlaxoSmithKline34602.23

AbbVie currently has a consensus target price of $115.75, indicating a potential upside of 9.26%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than GlaxoSmithKline.

Risk & Volatility

AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Valuation & Earnings

This table compares AbbVie and GlaxoSmithKline's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.63$7.88 billion$8.9411.87
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.41

AbbVie has higher earnings, but lower revenue than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
GlaxoSmithKline18.50%29.60%7.11%

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. AbbVie pays out 58.2% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 49 consecutive years and GlaxoSmithKline has raised its dividend for 1 consecutive years.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 10.0% of GlaxoSmithKline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AbbVie beats GlaxoSmithKline on 13 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Earnings & Valuation

This table compares Eli Lilly and and GlaxoSmithKline's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion7.88$8.32 billion$6.0430.37
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.41

Eli Lilly and has higher earnings, but lower revenue than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.9%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and has raised its dividend for 1 consecutive years and GlaxoSmithKline has raised its dividend for 1 consecutive years.

Profitability

This table compares Eli Lilly and and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
GlaxoSmithKline18.50%29.60%7.11%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Eli Lilly and and GlaxoSmithKline, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041102.73
GlaxoSmithKline34602.23

Eli Lilly and presently has a consensus target price of $196.40, indicating a potential upside of 6.80%. Given Eli Lilly and's stronger consensus rating and higher possible upside, research analysts plainly believe Eli Lilly and is more favorable than GlaxoSmithKline.

Institutional and Insider Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 10.0% of GlaxoSmithKline shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Eli Lilly and beats GlaxoSmithKline on 12 of the 16 factors compared between the two stocks.

Ad Street Signals
Breakthrough AI Tech Stock
Advanced breast cancer imaging tools could catapult this stock into the stratosphere.

GlaxoSmithKline Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$121.78+1.0%$217.92 billion$31.90 billion64.43Upcoming Earnings
Pfizer logo
PFE
Pfizer
2.3$37.11+0.1%$207.26 billion$51.75 billion23.94Analyst Revision
Novartis logo
NVS
Novartis
2.2$86.82+0.2%$198.22 billion$47.50 billion28.10
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.33+0.1%$193.40 billion$46.84 billion16.89Increase in Short Interest
Analyst Revision
AbbVie logo
ABBV
AbbVie
2.8$106.10+2.0%$190.99 billion$33.27 billion22.43Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$183.45+0.5%$175.04 billion$22.32 billion29.98Analyst Revision
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.4$70.61+0.2%$166.65 billion$18.30 billion26.55
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$63.86+0.4%$142.03 billion$26.15 billion-580.49Analyst Upgrade
Decrease in Short Interest
Analyst Revision
AstraZeneca logo
AZN
AstraZeneca
2.1$49.93+1.5%$129.10 billion$24.38 billion52.01Analyst Downgrade
Sanofi logo
SNY
Sanofi
1.5$50.33+0.3%$126.30 billion$40.00 billion21.51Decrease in Short Interest
Zoetis logo
ZTS
Zoetis
2.2$163.68+0.1%$77.65 billion$6.26 billion48.57Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$217.41+0.7%$56.14 billion$4.16 billion27.45Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.07+0.4%$53.60 billion$30.20 billion56.90
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$480.50+0.7%$51.11 billion$7.86 billion17.56Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.33+1.0%$33.80 billion$4.99 billion36.29
BeiGene logo
BGNE
BeiGene
1.3$302.33+0.7%$27.50 billion$428.21 million-14.96
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.38+2.2%$25.15 billionN/A0.00Increase in Short Interest
Analyst Revision
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$34.84+0.5%$22.73 billion$804.57 million27.01Decrease in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$92.07+0.5%$20.53 billion$1.30 billion25.16Insider Selling
Catalent logo
CTLT
Catalent
1.7$110.67+1.5%$18.56 billion$3.09 billion70.49Unusual Options Activity
Analyst Revision
CureVac logo
CVAC
CureVac
0.7$103.39+7.5%$17.88 billionN/A0.00Analyst Upgrade
Gap Down
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$139.01+2.0%$15.98 billion$219.75 million-17.75
Zai Lab logo
ZLAB
Zai Lab
1.4$163.54+1.4%$14.29 billion$12.98 million-53.97Analyst Report
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.39+0.8%$14.14 billion$1.70 billion17.94
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.58+0.6%$13.90 billion$3.07 billion-51.89
Grifols logo
GRFS
Grifols
1.3$18.00+0.8%$12.27 billion$5.71 billion16.07Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.99+2.1%$11.75 billion$16.89 billion-2.99Decrease in Short Interest
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.33+1.7%$10.60 billion$8.60 billion-5.57
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$63.32+1.0%$10.43 billion$2.32 billion52.33News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.80+1.9%$9.66 billionN/A0.00Increase in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$166.95+2.2%$9.20 billion$2.16 billion52.67Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$201.61+1.1%$8.88 billion$1.45 billion19.07Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$57.73+5.4%$8.13 billion$40.56 million-16.93Analyst Report
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$163.29+2.1%$8.09 billion$3.34 million-21.21
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$110.05+3.1%$7.14 billion$103.71 million-25.07Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.42+0.2%$6.83 billion$311.33 million-126.99Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.79+0.8%$6.71 billion$14.98 million-15.32
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.76+5.7%$6.64 billion$87.99 million-80.67Unusual Options Activity
News Coverage
Gap Down
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.59+2.1%$6.28 billion$150,000.00-21.50
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.20+2.6%$5.79 billion$1.12 billion87.92
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.52+4.8%$5.56 billion$380.83 million-9.40
Allakos logo
ALLK
Allakos
1.7$108.71+3.9%$5.55 billionN/A-39.68
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$97.53+4.6%$5.39 billion$66.51 million17.99Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.74+1.4%$5.36 billion$4.84 billion-678.89
Schrödinger logo
SDGR
Schrödinger
1.3$78.11+3.3%$5.29 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$81.34+3.7%$5.13 billion$1.00 billion-12.32Analyst Report
Gap Down
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$54.00+6.0%$4.73 billionN/A0.00Analyst Report
Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$76.41+4.8%$4.52 billionN/A-6.23Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.52+0.4%$4.31 billion$204.89 million-36.90
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.43+5.9%$4.20 billion$6.87 million-7.38Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.